Skip to content

The effect of remifentanil on awakening restlessness in patients undergoing laparoscopic cholecystectomy

Effect of remifentanil on arousal agitation in patients undergoing laparoscopic cholecystectomy: a single-center, prospective, double-blind randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080995
Enrollment
Unknown
Registered
2024-02-20
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis, Gallstone, Gallbladder polyp

Interventions

Remifentanil group:Remifentanil was continuously pumped 0.05ug/kg·min during postoperative recovery
Normal saline group:Saline is pumped continuously at the same rate during postoperative recovery

Sponsors

Weihai Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Age range from 18 to 65 years old; ? No serious complications, such as unstable angina, poor control of severe hypertension, etc.; ? Can cooperate with communication and complete follow-up indicators; ? Sign an informed consent form

Exclusion criteria

Exclusion criteria: ? Patients refused to participate in the study;? Previous history of major surgery, such as heart surgery, craniotomy, etc.There are contraindications to general anesthesia, such as severe hypertension, poorly controlled asthma, etc.? Allergic to investigational drugs;? Patients with mental illness can not cooperate with follow-up

Design outcomes

Primary

MeasureTime frame
Awakening restlessness level;

Secondary

MeasureTime frame
Patient recovery time;Patient's blood pressure, heart rate, respiratory rate, pulse oxygen saturation;Patient's nausea and vomiting, pain level, and pharyngeal pain level;

Countries

China

Contacts

Public ContactLi Quanlin

Weihai Municipal Hospital

li-quanlin@163.com+86 186 6035 3686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026